Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review.

INTRODUCTION: Bleeding is the most frequent complication in patients receiving venoarterial or venovenous extracorporeal membrane oxygenation (ECMO). Recombinant activated factor VII (rFVIIa) has been used in these patients with conflicting results. We describe our experience with rFVIIa for refractory bleeding in this setting and review the cases reported in the literature. METHODS: Clinical characteristics, demographics, bleeding, thrombotic complications, mortality, and rFVIIa administration were retrospectively collected for analysis from the electronic charts of the 15 patients in our intensive care unit who received rFVIIa while being given ECMO from January 2006 to March 2011. RESULTS: Fifteen patients received rFVIIa for persistent bleeding under venoarterial (n=11) or venovenous (n=4) ECMO. Bleeding dramatically decreased in 14 patients, without a major thrombotic event, except in one patient in whom a major stroke could not be ruled out. Two circuits were changed within the 48 hours after rFVIIa administration for clots in the membrane and decreased oxygenation but without massive clotting. The mortality rate was 60%. CONCLUSIONS: rFVIIa use for intractable hemorrhaging in patients receiving ECMO controlled bleeding, without major thrombotic events, and with 60% dying. Hence, its use warrants discussion, and clinicians should be aware of the possibility of potentially life-threatening systemic thrombosis, emboli, or circuit clotting. Whether rFVIIa can save the lives of such patients remains to be determined.

Risk Factors of AKI in Acute Respiratory Distress Syndrome: A Time-Dependent Competing Risk Analysis on Severe COVID-19 Patients.

Introduction: Acute kidney injury (AKI) is frequently observed in patients with COVID-19 admitted to intensive care units (ICUs). Observational studies suggest that cardiovascular comorbidities and mechanical ventilation (MV) are the most important risk factors for AKI. However, no studies have investigated the renal impact of longitudinal covariates such as drug treatments, biological variations, and/or MV parameters. Methods: We performed a monocentric, prospective, longitudinal analysis to identify the dynamic risk factors for AKI in ICU patients with severe COVID-19. Results: Seventy-seven patients were included in our study (median age: 63 [interquartile range, IQR: 53-73] years; 58 (75%) men). Acute kidney injury was detected in 28 (36.3%) patients and occurred at a median time of 3 [IQR: 2-6] days after ICU admission. Multivariate Cox cause-specific time-dependent analysis identified a history of hypertension (cause-specific hazard (CSH) = 2.46 [95% confidence interval, CI: 1.04-5.84]; P = .04), a high hemodynamic Sequential Organ Failure Assessment score (CSH = 1.63 [95% CI: 1.23-2.16]; P < .001), and elevated Paco2 (CSH = 1.2 [95%CI: 1.04-1.39] per 5 mm Hg increase in Pco2; P = .02) as independent risk factors for AKI. Concerning the MV parameters, positive end-expiratory pressure (CSH = 1.11 [95% CI: 1.01-1.23] per 1 cm H2O increase; P = .04) and the use of neuromuscular blockade (CSH = 2.96 [95% CI: 1.22-7.18]; P = .02) were associated with renal outcome only in univariate analysis but not after adjustment. Conclusion: Acute kidney injury is frequent in patients with severe COVID-19 and is associated with a history of hypertension, the presence of hemodynamic failure, and increased Pco2. Further studies are necessary to evaluate the impact of hypercapnia on increasing the effects of ischemia, particularly in the most at-risk vascular situations.

Introduction: L'insuffisance rénale aiguë (IRA) est fréquemment observée chez les patients atteints de COVID-19 admis dans les unités de soins intensifs (USI). Des études observationnelles suggèrent que les comorbidités cardiovasculaires et la ventilation mécanique (VM) seraient les plus importants facteurs de risque de l'IRA. Aucune étude n'a cependant examiné l'impact sur la fonction rénale de covariables longitudinales telles que les traitements médicamenteux, les variations biologiques et/ou les paramètres de la VM. Méthodologie: Nous avons procédé à une analyse prospective et longitudinale dans un seul centre hospitalier afin d'identifier les facteurs de risque dynamiques de l'IRA chez les patients hospitalisés aux USI en raison d'une forme grave de la COVID-19. Résultats: Soixante-dix-sept patients ont été inclus dans notre étude (75 % d'hommes [n=58]; âge médian: 63 ans [ÉIQ: 53-73]). L'IRA a été détectée chez 28 patients (36,3 %) et est survenue dans un délai médian de 3 jours (ÉIQ: 2-6 jours) après l'admission à l'USI. Une analyse de Cox multivariée, spécifique à la cause et tenant compte du temps, a permis de dégager les éléments suivants comme étant des facteurs de risque indépendants pour l'IRA: des antécédents d'hypertension (probabilité par cause [PPC]=2,46 [IC 95 %: 1,04-5,84]; p=0,04), un score SOFA hémodynamique élevé (PPC=1,63 [IC 95 %: 1,23-2,16]; p<0,001) et une concentration élevée de PaCO2 (PPC=1,2 [IC 95 %: 1,04-1,39] pour chaque augmentation de 5 mmHg de pCO2; p = 0,02). En ce qui concerne les paramètres de la VM, une pression expiratoire positive (PPC=1,11 [IC 95 %: 1,01-1,23] pour chaque augmentation de 1 cm H2O; p = 0,04) et l'utilisation d'un bloc neuromusculaire (PPC=2,96 [IC 95 %: 1,22-7,18]; p=0,02) ont été associés à l'IRA dans l'analyse univariée seulement, et non après ajustement. Conclusion: L'IRA est fréquente chez les patients atteints d'une forme grave de COVID-19 et elle est associé à des antécédents d'hypertension, à la présence d'une instabilité hémodynamique et à une augmentation de la pCO2. D'autres études sont nécessaires pour évaluer l'impact de l'hypercapnie sur l'augmentation des effets de l'ischémie, en particulier dans les situations vasculaires les plus à risque.

Bedside echocardiography in critically ill patients: a true hemodynamic monitoring tool.

Echocardiography is a versatile, accurate and noninvasive tool suited to examination of shocked patients. Since the 1980s, intensive care practitioners have used ultrasound widely for hemodynamic evaluation and for cardiac anatomy visualization. This article will describe transthoracic and transesophageal echocardiography, their scope, and the classic windows needed to interpret the examination properly. We will also report the main indications of echocardiography and the corresponding parameters. Finally, we will indicate educational programs and define minimum training that enable self-sufficiency.

Ten good reasons why everybody can and should perform cardiac ultrasound in the ICU.

Critical care ultrasonography (CCUS) has been defined as an ultrasound evaluation of the heart, abdomen, pleura and lungs at the bedside by the intensivist, 24/7. Within CCUS, critical care echocardiography (CCE) is used to assess cardiac function and more generally haemodynamics. Experts in haemodynamics have published a 'consensus of 16' regarding an update on haemodynamic monitoring. They reported the ten key properties of an 'ideal' haemodynamic monitoring system, which perfectly match the ten good reasons we describe here for performing CCE in critically ill patients. Even though unfortunately no evidence-based medicine study is available to support this review, especially regarding CCE-related improvement of outcome, many clinical studies have demonstrated that CCE provides measurements of relevant, accurate, reproducible and interpretable variables, is easy to use, readily available, has a rapid response time, causes no harm, and is cost-effective. Whether it is operator-independent is obviously more debatable and is discussed in this review. All these characteristics are arguments for the extensive use of CCE by intensivists. This is why experts in the field have recommended that a basic level of CCE should be included in the training of all intensivists.